دورية أكاديمية
أعرض في EDS

Ensemble-based classification using microRNA expression identifies a breast cancer patient subgroup with an ultralow long-term risk of metastases.

التفاصيل البيبلوغرافية
العنوان: Ensemble-based classification using microRNA expression identifies a breast cancer patient subgroup with an ultralow long-term risk of metastases.
المؤلفون: Block I; Department of Clinical Genetics, Odense University Hospital, Odense, Denmark., Burton M; Department of Clinical Genetics, Odense University Hospital, Odense, Denmark.; Human Genetics, Department of Clinical Research, University of Southern Denmark, Odense, Denmark.; Clinical Genome Center, University of Southern Denmark and Region of Southern Denmark, Odense, Denmark., Sørensen KP; Department of Clinical Genetics, Odense University Hospital, Odense, Denmark., Larsen MJ; Department of Clinical Genetics, Odense University Hospital, Odense, Denmark.; Human Genetics, Department of Clinical Research, University of Southern Denmark, Odense, Denmark., Do TTN; Department of Clinical Genetics, Odense University Hospital, Odense, Denmark.; Human Genetics, Department of Clinical Research, University of Southern Denmark, Odense, Denmark., Bak M; Department of Pathology, Odense University Hospital, Odense, Denmark.; Department of Pathology, Hospital of Southwest Jutland, Esbjerg, Denmark., Cold S; Department of Oncology, Odense University Hospital, Odense, Denmark., Thomassen M; Department of Clinical Genetics, Odense University Hospital, Odense, Denmark.; Human Genetics, Department of Clinical Research, University of Southern Denmark, Odense, Denmark.; Clinical Genome Center, University of Southern Denmark and Region of Southern Denmark, Odense, Denmark., Tan Q; Human Genetics, Department of Clinical Research, University of Southern Denmark, Odense, Denmark.; Clinical Genome Center, University of Southern Denmark and Region of Southern Denmark, Odense, Denmark.; Epidemiology, Department of Public Health, University of Southern Denmark, Odense, Denmark., Kruse TA; Department of Clinical Genetics, Odense University Hospital, Odense, Denmark.; Human Genetics, Department of Clinical Research, University of Southern Denmark, Odense, Denmark.; Clinical Genome Center, University of Southern Denmark and Region of Southern Denmark, Odense, Denmark.
المصدر: Cancer medicine [Cancer Med] 2024 May; Vol. 13 (9), pp. e7089.
نوع المنشور: Journal Article; Research Support, Non-U.S. Gov't
اللغة: English
بيانات الدورية: Publisher: John Wiley & Sons Ltd Country of Publication: United States NLM ID: 101595310 Publication Model: Print Cited Medium: Internet ISSN: 2045-7634 (Electronic) Linking ISSN: 20457634 NLM ISO Abbreviation: Cancer Med Subsets: MEDLINE
أسماء مطبوعة: Original Publication: [Malden, MA] : John Wiley & Sons Ltd., c2012-
مواضيع طبية MeSH: Breast Neoplasms*/genetics , Breast Neoplasms*/pathology , Breast Neoplasms*/metabolism , MicroRNAs*/genetics , Biomarkers, Tumor*/genetics, Humans ; Female ; Middle Aged ; Aged ; Neoplasm Recurrence, Local/genetics ; Neoplasm Recurrence, Local/pathology ; Adult ; Gene Expression Profiling/methods ; Gene Expression Regulation, Neoplastic ; Risk Assessment/methods ; Neoplasm Metastasis ; Prognosis
مستخلص: Background: Current clinical markers overestimate the recurrence risk in many lymph node negative (LNN) breast cancer (BC) patients such that a majority of these low-risk patients unnecessarily receive systemic treatments. We tested if differential microRNA expression in primary tumors allows reliable identification of indolent LNN BC patients to provide an improved classification tool for overtreatment reduction in this patient group.
Methods: We collected freshly frozen primary tumors of 80 LNN BC patients with recurrence and 80 recurrence-free patients (mean follow-up: 20.9 years). The study comprises solely systemically untreated patients to exclude that administered treatments confound the metastasis status. Samples were pairwise matched for clinical-pathological characteristics to minimize dependence of current markers. Patients were classified into risk-subgroups according to the differential microRNA expression of their tumors via classification model building with cross-validation using seven classification methods and a voting scheme. The methodology was validated using available data of two independent cohorts (n = 123, n = 339).
Results: Of the 80 indolent patients (who would all likely receive systemic treatments today) our ultralow-risk classifier correctly identified 37 while keeping a sensitivity of 100% in the recurrence group. Multivariable logistic regression analysis confirmed independence of voting results from current clinical markers. Application of the method in two validation cohorts confirmed successful classification of ultralow-risk BC patients with significantly prolonged recurrence-free survival.
Conclusion: Profiles of differential microRNAs expression can identify LNN BC patients who could spare systemic treatments demanded by currently applied classifications. However, further validation studies are required for clinical implementation of the applied methodology.
(© 2024 The Authors. Cancer Medicine published by John Wiley & Sons Ltd.)
References: Acta Oncol. 2008;47(4):506-24. (PMID: 18465317)
PLoS One. 2013;8(1):e52517. (PMID: 23382819)
Gene. 2017 Jul 1;619:10-20. (PMID: 28359916)
Lancet. 2005 May 14-20;365(9472):1687-717. (PMID: 15894097)
Breast Cancer Res. 2017 Nov 14;19(1):120. (PMID: 29137653)
Acta Oncol. 2008;47(4):525-36. (PMID: 18465318)
Sci Rep. 2018 Oct 31;8(1):16138. (PMID: 30382159)
Oncotarget. 2017 Jan 3;8(1):393-407. (PMID: 27880723)
Acta Oncol. 2013 Jan;52(1):91-101. (PMID: 22934555)
Nat Genet. 2015 Jul;47(7):692-5. (PMID: 26111507)
Cancer Med. 2024 May;13(9):e7089. (PMID: 38676390)
ScientificWorldJournal. 2012;2012:380495. (PMID: 23251101)
Eur J Cancer. 2017 Apr;75:284-298. (PMID: 28259011)
Cell Cycle. 2020 Nov;19(21):2811-2825. (PMID: 33054543)
Breast Cancer Res Treat. 2014 Feb;144(1):103-11. (PMID: 24469641)
Int J Cancer. 2015 Mar 1;136(5):E359-86. (PMID: 25220842)
Nucleic Acids Res. 2002 Jan 1;30(1):207-10. (PMID: 11752295)
Nat Methods. 2014 Aug;11(8):809-15. (PMID: 24973947)
Oncotarget. 2018 Jan 9;9(10):9030-9042. (PMID: 29507672)
J Clin Oncol. 2022 Apr 20;40(12):1335-1345. (PMID: 35061525)
Dis Markers. 2022 Jul 25;2022:6899777. (PMID: 35923244)
Nature. 2002 Jan 31;415(6871):530-6. (PMID: 11823860)
Breast Cancer Res. 2015 Apr 11;17:55. (PMID: 25887545)
Br J Cancer. 2015 Jul 14;113(2):290-8. (PMID: 26057454)
JAMA Oncol. 2017 Nov 01;3(11):1503-1510. (PMID: 28662222)
Clin Cancer Res. 2020 Jan 1;26(1):171-182. (PMID: 31558478)
Lancet Oncol. 2014 May;15(6):e234-42. (PMID: 24807866)
N Engl J Med. 2017 Nov 9;377(19):1836-1846. (PMID: 29117498)
Nature. 2013 May 16;497(7449):378-82. (PMID: 23644459)
Front Oncol. 2021 Apr 12;11:645682. (PMID: 33912460)
Breast Cancer Res. 2017 May 22;19(1):58. (PMID: 28532503)
Proc Natl Acad Sci U S A. 2008 Sep 2;105(35):13021-6. (PMID: 18755890)
J Breast Cancer. 2016 Jun;19(2):148-55. (PMID: 27382390)
Biomed Res Int. 2014;2014:651751. (PMID: 25101291)
J Clin Oncol. 2017 Aug 20;35(24):2838-2847. (PMID: 28692382)
Cancer Inform. 2007 Feb 11;2:59-77. (PMID: 19458758)
Breast Cancer Res Treat. 2017 Jul;164(2):461-466. (PMID: 28451965)
Breast Cancer Res. 2015 Feb 18;17:21. (PMID: 25849621)
N Engl J Med. 2002 Dec 19;347(25):1999-2009. (PMID: 12490681)
CA Cancer J Clin. 2018 Nov;68(6):394-424. (PMID: 30207593)
Bioinformatics. 2003 Aug 12;19(12):1484-91. (PMID: 12912828)
Nature. 2012 Apr 18;486(7403):346-52. (PMID: 22522925)
معلومات مُعتمدة: DAWN2020 University of Southern Denmark; DBCG-TIBCAT The Danish Council for Strategic Research; A. J. Andersen & Hustrus Fond; Meta & Håkon Baggers Fond; Free Research Fond of the Odense University Hospital; Kræftens Bekæmpelse; Inge & Jørgen Larsens Mindelegat; Dansk Kræftforsknings Fond; Overlægerådets Legatudvalg; 09-061677/FSS Natur og Univers, Det Frie Forskningsråd; 7016-00346B/FSS Natur og Univers, Det Frie Forskningsråd; Lundbeck Foundation; Frimodt-Heineke Fonden; Regionernes Medicin- og behandlingspulje; Direktør Jacob Madsen & Hustru Olga Madsens Fond; Danish Ministry of the Interior; Fru Ingeborg Albinus Larsens Mindelegat; Breast Friends; Fonden til Lægevidenskabens Fremme; Fonden af 1870; Harboefonden
فهرسة مساهمة: Keywords: low‐risk breast cancer; lymph node negative; microRNA‐based recurrence prediction; overtreatment reduction; systematically untreated
المشرفين على المادة: 0 (MicroRNAs)
0 (Biomarkers, Tumor)
تواريخ الأحداث: Date Created: 20240427 Date Completed: 20240427 Latest Revision: 20240429
رمز التحديث: 20240429
مُعرف محوري في PubMed: PMC11053369
DOI: 10.1002/cam4.7089
PMID: 38676390
قاعدة البيانات: MEDLINE
الوصف
تدمد:2045-7634
DOI:10.1002/cam4.7089